Kymab Ltd of the UK has appointed Duncan Casson, formerly with PanGenetics and Cambridge Antibody Technology (CAT), to be its chief development officer with responsibility for the preclinical, manufacturing, clinical and regulatory development of the company's future antibody therapy portfolio which is based on transgenic mouse technology. Dr Casson was previously chief operating officer of PanGenetics BV and vice president of programme management and manufacturing at CAT.
Simultaneously the company appointed Ken Smith, a professor medicine at the University of Cambridge, to its scientific advisory board, and Dr George Vassiliou of the Wellcome Trust as a senior clinical fellow with a specialisation in haematological cancer.
Kymab announced the appointments on 18 March 2013.
Copyright 2013 Evernow Publishing Ltd.